Surmodics (FRA:SU6) Cyclically Adjusted Revenue per Share: €6.94 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:SU6 Surmodics Inc FRA:SU6
51 GF Score
Price €36.40
View Full Analysis

What is Surmodics Cyclically Adjusted Revenue per Share?

Surmodics FRA:SU6 51 Cyclically Adjusted Revenue per Share is €6.94 as of Jun. 2025. GuruFocus rates FRA:SU6 with a GF Score™ of 51/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Surmodics's adjusted revenue per share for the three months ended in Jun. 2025 was €1.795. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €6.94 for the trailing ten years ended in Jun. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-09-04), Surmodics's current stock price is €36.40. Surmodics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2025 was €6.94. Surmodics's Cyclically Adjusted PS Ratio of today is 5.24.


Surmodics  (FRA:SU6) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Surmodics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=36.40/6.94
=5.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Surmodics Cyclically Adjusted Revenue per Share Related Terms


Surmodics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Surmodics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surmodics Cyclically Adjusted Revenue per Share Chart

Surmodics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.53 5.22 6.95 6.84 7.06

Surmodics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.29 7.06 7.67 7.64 6.94

FRA:SU6 vs CBLL, OFIX, LAB: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Surmodics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surmodics Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Surmodics's Cyclically Adjusted PS Ratio falls into.


FRA:SU6
51GF Score
Surmodics Inc FRA:SU6
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Surmodics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Surmodics's adjusted Revenue per Share data for the three months ended in Jun. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2025 (Change)*Current CPI (Jun. 2025)
=1.795/322.5610*322.5610
=1.795

Current CPI (Jun. 2025) = 322.5610.

Surmodics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201509 1.173 237.945 1.590
201512 1.152 236.525 1.571
201603 1.137 238.132 1.540
201606 1.338 241.018 1.791
201609 1.219 241.428 1.629
201612 1.252 241.432 1.673
201703 1.219 243.801 1.613
201706 1.183 244.955 1.558
201709 1.261 246.819 1.648
201712 1.100 246.524 1.439
201803 1.148 249.554 1.484
201806 1.441 251.989 1.845
201809 1.487 252.439 1.900
201812 1.414 251.233 1.815
201903 1.456 254.202 1.848
201906 1.570 256.143 1.977
201909 2.029 256.759 2.549
201912 1.478 256.974 1.855
202003 1.502 258.115 1.877
202006 1.732 257.797 2.167
202009 1.375 260.280 1.704
202012 1.341 260.474 1.661
202103 2.103 264.877 2.561
202106 1.432 271.696 1.700
202109 1.447 274.310 1.702
202112 1.467 278.802 1.697
202203 1.703 287.504 1.911
202206 1.688 296.311 1.838
202209 1.883 296.808 2.046
202212 1.683 296.797 1.829
202303 1.811 301.836 1.935
202306 3.442 305.109 3.639
202309 1.863 307.789 1.952
202312 1.987 306.746 2.089
202403 2.073 312.332 2.141
202406 1.989 314.175 2.042
202409 2.110 315.301 2.159
202412 2.008 315.605 2.052
202503 1.820 319.799 1.836
202506 1.795 322.561 1.795

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €6.94 mean?
Surmodics (FRA:SU6) has a Cyclically Adjusted Revenue per Share of €6.94 as of Jun. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Surmodics and its competitors.
Is Surmodics' Cyclically Adjusted Revenue per Share too high?
Surmodics' current Cyclically Adjusted Revenue per Share is €6.94. Overall, Surmodics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Surmodics' Cyclically Adjusted Revenue per Share compare to CBLL and OFIX?
Surmodics' Cyclically Adjusted Revenue per Share of €6.94 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Surmodics and its competitors. Surmodics's current Cyclically Adjusted Revenue per Share is €6.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surmodics stock overvalued right now?
Surmodics (FRA:SU6) has a current Cyclically Adjusted Revenue per Share of €6.94. The current Cyclically Adjusted Revenue per Share is €6.94. Surmodics' overall GF Score™ is 51/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Surmodics (FRA:SU6), the current Cyclically Adjusted Revenue per Share is €6.94 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Surmodics Business Description

Address 9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
51GF Score

Get the complete analysis for FRA:SU6

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€36.40
Price